ReiThera Srl – previously Okairos – was founded by an experienced team which pioneered the development, manufacture and early clinical testing of non-human origin adeno-vectored vaccines for major infectious diseases such as hepatitis C, malaria, HIV, Respiratory Syncytial Virus, and Ebola. Okairos was acquired by GlaxoSmithKline (“GSK”) in May 2013.
With fully-equipped, state of the art R&D laboratories and GMP production facility located in Rome, and auxiliary laboratories in Naples, ReiThera delivers reliable solutions at every step of early development to engineering and industrial process. From early development to final QP release, we provide tailored and effective solutions to meet the industry’s demanding regulatory standards and the expectations of the fast-growing market of gene-delivery technologies.
By innovating on gene delivery systems, manufacturing methods, and step-ahead regulatory compliance strategies, we continue — in seamless cooperation with our partners and clients, as well through our own R&D projects — to fulfill the requirements and exceed the challenges of this new and still untapped field.